Obstructive sleep apnea (OSA) is a common and often underdiagnosed condition (Motamedi, McClary, & Amedee, 2009) . It is characterized by recurrent episodes of partial (hypopnea) or a near-complete (apnea) obstruction of the pharyngeal airway during sleep (Spicuzza, Caruso, & Di Maria, 2015) . These obstructive events are associated with drops in oxygen saturation and are usually terminated by arousals, resulting in fragmentation of sleep (Eckert & Malhotra, 2008; Schroder & O'Hara, 2005) . Epidemiological studies have shown that 13% of men and 6% of women have OSA of at least moderate severity (Apnea-Hypopnea Index [AHI] Ն 15; Peppard et al., 2013) . The condition manifests as snoring, nocturnal gasping and choking, excessive daytime sleepiness, reduced quality of life, and fatigue (Gupta, Chandra, Verm, & Kumar, 2010) . OSA also increases the risk of a constellation of health-related issues, including cardiovascular problems, such as hypertension (Marin et al., 2012) , stroke (Yaggi et al., 2005) , and myocardial infarction (Marin, Carrizo, & Kogan, 1998) , as well as type 2 diabetes (Tasali, Mokhlesi, & Van Cauter, 2008) and metabolic syndromes (Vgontzas, Bixler, & Chrousos, 2005) .
Previous research (e.g., Harris, Glozier, Ratnavadivel, & Grunstein, 2009; Schroder & O'Hara, 2005; Nanthakumar, Bucks, & Skinner, 2016) has highlighted the association between OSA and depression. Cardinal symptoms of depression include low mood, anhedonia, hypersomnia/insomnia, fatigue/loss of energy, feelings of worthlessness/guilt, concentration difficulty/indecisiveness, psychomotor agitation/retardation, suicidal ideation, appetite changes, and weight gain/loss (Diagnostic and Statistical Manual of Mental Disorders [Fifth edition, ; American Psychiatric Association, 2013). In addition, depression frequently presents with symptoms of anxiety and stress, such as excessive worry, phobia, and irritability (DSM-5; American Psychiatric Association, 2013). Depression questionnaires are commonly used to assess these different features of depression in clinical and research settings (Coyne, Thompson, Klinkman, & Nease Jr., 2002) . The prevalence rates of current depression in OSA when using depression questionnaires (using standardized cutoffs) in clinicalbased and population-based studies have ranged from 8% to 68% (Nanthakumar et al., 2016) . The assessment of depression in OSA is confounded by the overlap in symptoms between the two conditions, such as insomnia, fatigue, decreased libido, irritability, weight changes, and cognitive difficulties (Harris et al., 2009; Nanthakumar et al., 2016) . Different depression questionnaires have varying proportions of shared symptoms, and increasing symptom overlap is associated with increasing prevalence of depression in OSA (Nanthakumar et al., 2016) . This overlap in symptomatology makes it difficult to determine which symptoms reliably identify depression in the presence of OSA.
The Depression, Anxiety, and Stress Scale (DASS; Lovibond & Lovibond, 1995) is a frequently used measure of overall negative affect in clinical and non-clinical populations. The DASS contains three subscales that assess depression, anxiety, and stress symptoms, and it is available in the original 42-item (14 items per subscale) and a shortened 21-item form (DASS-21; 7 items per subscale). As previously noted, anxiety and stress symptoms are associated features of depression. Previous studies have shown that the scale has sound psychometric properties of a correlated, threefactor structure (depression, anxiety, and stress) across clinical and non-clinical samples (Antony, Bieling, Cox, Enns, & Swinson, 1998; Henry & Crawford, 2005) , including other chronic disease samples (e.g., persistent pain; Wood, Nicholas, Blythe, Asghari, & Gibson, 2010) .
Measurement invariance assesses the equivalence of the factor structure parameters (i.e., factor structure, factor loadings, factor means, item loadings) across different samples (Byrne & Watkins, 2003; Nye, Roberts, Saucier, & Zhou, 2008; Steenkamp & Baumgartner, 1998) . In the absence of measurement invariance, comparisons on a measure are problematic and ambiguous. That is, one cannot determine if an observed difference between samples represents a true difference in the underlying construct or systematic biases in the way people from different samples perceive and respond to items (Byrne & Watkins, 2003; Cheung & Rensvold, 2002; Horn & McArdle, 1992) . When examining the symptoms assessed in the DASS-21 in an OSA sample, there are two underlying factors predicting a person's score: (a) the degree to which there are true differences in the way that the person is genuinely depressed/anxious/stressed and (b) the degree to which they are also endorsing items as a function of their OSA. Therefore, questionnaires that consist of a high proportion of overlapping symptoms with OSA may not be assessing genuine depression/anxiety/ stress in OSA.
In a recent meta-analysis by Nanthakumar et al. (2016) , symptoms of depression in commonly used depression scales were categorized into overlapping and non-overlapping symptoms. These categories can also be used to divide the DASS-21 items. Non-overlapping symptoms of depression reflect anhedonia (e.g., "I felt that I had nothing to look forward to") or depressive cognitions (e.g., "I felt I was not worth much as a person"). Non-overlapping symptoms of anxiety assess anxious cognitions (e.g., "I felt scared without any good reason") and non-overlapping stress symptoms assess stress cognitions (e.g., "I felt that I was using a lot of nervous energy") and agitation/restlessness symptoms (e.g., "I found myself getting agitated"). By contrast, the Anxiety subscale assesses overlapping somatic symptoms (e.g., "I was aware of dryness of my mouth" and "I experienced breathing difficulty" [e.g., excessively rapid breathing, breathlessness in the absence of physical exertion]), and the Stress subscale assesses overlapping irritability symptoms (e.g., "I felt that I was rather touchy" and "I was intolerant of anything that kept me from getting on with what I was doing"), but the Depression subscale contains no overlapping symptoms. No study to date has examined the impact of overlapping symptoms on the suitability of the total DASS-21 in an OSA sample compared with a non-OSA sample.
The present study examined (a) if Lovibond and Lovibond's (1995) correlated three-factor structure holds in an OSA sample compared with a non-OSA sample, and (b) measurement invariance across these samples. We hypothesized that there may be a lack of measurement invariance across samples, primarily due to differential fit in the Anxiety and/or Stress subscales, because of symptom overlap.
Method

Participants and Protocol
Participants were selected from the Busselton Healthy Ageing Study. Busselton is a coastal community in the southwest of Western Australia with a relatively stable population of predominantly European descent (James et al., 2013 Sleep apnea screening devices were offered to participants to use over one night at home. Participants who received current continuous positive airway pressure (CPAP) or mandibular advancement splint therapy for sleep apnea were excluded from the sleep apnea screening study. Sleep studies were conducted using dual-channel (oximetry and nasal pressure) ApneaLink devices (Resmed, Sydney, Australia). Participants were instructed on how to fit and operate the units, and the monitors were returned to the study center the following day. Data were downloaded and automatically analyzed using ApneaLink software version 8.00. Scores of respiratory disturbances including AHI, number of snoring events, and oxygen desaturation were recorded. The ApneaLink has been found to be a good screening tool for OSA (Crowley et al., 2013; Erman, Stewart, Einhorn, Gordon, & Casal, 2007; Gantner et al., 2010; Ng et al., 2009 ). An AHI of Ն15 on an ApneaLink has adequate sensitivity (66.7-100.0%) and specificity (88.5-100.0%) in indicating the presence of OSA compared with full polysomnography (PSG; see Crowley et al., 2013; Erman et al., 2007; Ng et al., 2009; Ragette, Wang, Weinreich, & Teschler., 2010) . The study received approval from the University of Western Australia Human Research Ethics Committee.
OSA Sample
There were 2,129 individuals recruited at baseline who completed an overnight sleep study, of whom 285 (13.39%) had an AHI of Ն15 using the ApneaLink, and reported no other sleep disorder (based on self-reported medical history). The mean age was 58 years (SD ϭ 5.26; range ϭ 45-68 years), mean body mass index (BMI) was 31.03 (SD ϭ 6.12; range ϭ 17.70 -65.70), and mean AHI was 24.68 (SD ϭ 11.75; range 15-89). One hundred and nine (38.25%) individuals were female.
Age-and Gender-Matched Controls (Non-OSA Sample)
From the remaining individuals whose AHI was Ͻ15 and who reported no sleep disorder, 285 (15.46%) age-and gender-matched individuals were selected. These individuals were selected by pairing an OSA participant to a non-OSA participant who was of the same gender and age Ϯ5 years of the age of the OSA participant. The mean age was 58 years (SD ϭ 5.24; range ϭ 45-68 years), mean BMI was 30.64 (SD ϭ 4.20; range ϭ 21.87-44.42), and mean AHI was 5.16 (SD ϭ 3.99; range: 0 -14). The AHI was Յ5 in 59.30% and Յ10 in 88.10% of individuals, and 109 (38.25%) were female. There was no significant difference in BMI or age between the two samples (p Ͼ .05). As expected, AHI was significantly lower in the age-and gender-matched controls (p Ͻ .01).
Materials
The DASS-21 (Lovibond & Lovibond, 1995 ) is a 21-item selfreport questionnaire designed to measure depression, anxiety, and stress symptoms. It is the short form of Lovibond and Lovibond's (1995) 42-item version, from which the 21 highest loading items were selected (7 from each of the 3 subscales). Participants indicate the degree to which they felt negative affect symptoms over the past week, from 0 (did not apply to me at all) to 3 (applied to me very much, or most of the time). Scale scores range from 0 to 21, but are doubled so as to be comparable to the 42-item scale, with higher scores indicating greater depression, anxiety, and stress, respectively. The subscales have good internal reliability (Depression subscale: Cronbach's ␣ ϭ .82 to .84; Anxiety subscale: Cronbach's ␣ ϭ .74 to .81; Stress subscale: Cronbach's ␣ ϭ .74 to .88; Norton, 2007) as well as good convergent and discriminant validity (Henry & Crawford, 2005) , and the full scale has a reliable correlated three-factor structure in clinical and nonclinical samples (Antony et al., 1998; Henry & Crawford, 2005) .
Data Analysis Plan
Data screening and descriptive analyses were performed using SPSS 19.0 for Windows, IBM (2015B). Confirmatory factor analysis (CFA) and measurement invariance analyses were performed using MPlus, version 3.0 (Muthén & Muthén, 1998 and dMACS (Nye & Drasgow, 2011) .
CFA. CFA was used to examine Lovibond and Lovibond's (1995) correlated three-factor structure of the DASS-21 in the OSA and non-OSA samples. As recommended by Muthén and Muthén (1998-2011) , we used maximum likelihood estimation with robust standard errors because this is robust to non-normality.
2 was used to evaluate overall model fit, along with the comparative fit index (CFI; Bentler, 1990 ), Tucker-Lewis Index (TLI; Tucker & Lewis, 1973) , root-mean-square error of approximation (RMSEA; Steiger & Lind, 1980) , and standardized root mean squared residual (SRMR; Jöreskog & Sörbom, 1998) . Recommended cutoffs for the fit indexes were CFI: Ն.95, TLI: Ն.95, RMSEA: Յ.050, and SRMR: Յ.060 (Hu & Bentler, 1999) .
Measurement invariance. Provided that the correlated threefactor structure of the DASS-21 was an acceptable fit in the non-OSA sample, the multigroup confirmatory factor analysis (MGCFA) approach for testing measurement invariance was conducted by performing configural, metric, and then scalar invariance testing (Cheung & Rensvold, 2002; Vandenberg & Lance, 2000) . A 2 difference test using scaling correction factors for MLR across unconstrained and a series of constrained measurement models was performed to examine the different levels of measurement invariance (Muthén & Muthén, 1998 . The unconstrained model is estimated without any conditions, whereas the constrained models are estimated with the condition that one or more specified factor parameters would have the same value for both samples (Muthén & Muthén, 1998 . A lack of measurement invariance is indicated by a statistically significant 2 difference between the respective pair of models (Muthén & Muthén, 1998 ) and a ⌬CFI of Ͼ.002 (Meade, Johnson, & Braddy, 2008 ).
Configural invariance was tested first, which evaluates whether the same overall factor structure holds in the two samples (Cheung & Rensvold, 2002; Milfont & Fischer, 2010;  This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. Vandenberg & Lance, 2000) . Configural invariance is a prerequisite for higher levels of equivalence testing (i.e., metric and scalar invariance). If configural invariance was met, then metric invariance and scalar invariance were tested. Metric invariance evaluates the degree to which the factor loadings are equal across samples, and scalar invariance assesses the equality of intercept terms (i.e., means/thresholds) between the samples (Cheung & Rensvold, 2002; Milfont & Fischer, 2010; Vandenberg & Lance, 2000) . If measurement non-invariance was found, then CFA mean and covariance structure (MACS) analysis to examine the source of noninvariance by assessing DIF was conducted using dMACS (see Nye & Drasgow, 2011) , evaluating (a) which items are being responded to in a different way between the samples and (b) the magnitude of these differences between the samples (i.e., DIF). Effect sizes were compared to Cohen's (1988) guidelines (0.20 ϭ small, 0.50 ϭ medium, 0.80 ϭ large).
Results
Descriptive Statistics
Means, SDs, ranges, ␣ values, and difference in means for the three subscale scores for each sample are shown in Table 1 .
CFA
The correlated three-factor structure (Model 1a) had fairly poor fit (see Table 2 ). In theory, the requirement for any item to load exclusively on a single latent construct has been problematic in CFA because items within a measure can sometimes be multidimensional (see Morin, Arens, & Marsh, 2016) , which may account for inadequate fit of the correlated three-factor model. Given that work from Nanthakumar et al. (2016) and Fried (2015) suggests that depression, anxiety, and stress symptoms are multidimensional and may cluster into subfacets (e.g., anhedonia, cognition, cognitive symptoms), we allowed error terms within subscales to correlate. As in Szabó (2010) , correlations were based on modification indices (MIs) supported by a conceptual rationale, restricting correlated errors to item pairs within a subscale. Correlating error terms to improve model fit was recommended by Henry and Crawford (2005) and has been applied in other studies (e.g., Asghari, Saed, & Dibajnia, 2008; Szabó, 2010; Wood et al., 2010 ) that have examined the factor structure of the DASS-21. Correlated pairs included four Depression item pairs reflecting anhedonia or cognition symptoms (range of MIs ϭ 4.03-47.20), six item pairs from the Anxiety subscale reflecting consequences of panic/anxiety (range of MIs ϭ 6.12-13.54), and one item pair from the Stress subscale reflecting restlessness (range of MI ϭ 9.32). Permitting correlated errors (see Table 3 ) produced a well-fitting model (Model 1b, Table 2 ). When this model was then tested with the OSA sample (Model 2, Table 2), fit statistics indicated less than ideal fit according to the significant 2 , TLI, and CFI; therefore, we proceeded to invariance testing.
Measurement Invariance
Model 1b served as the baseline model in evaluating measurement invariance across samples. Results from configural invariance analysis indicated that the ⌬ 2 was significant (p Ͻ .001) and ⌬CFI ϭ .003. Therefore, further invariance analyses were not conducted.
Given the lack of configural invariance, dMACS was used to investigate the source of measurement non-invariance by assessing DIF. MPlus estimates of the item parameters that were used to calculate the effect sizes for the Depression, Anxiety, and Stress subscales are provided in Table 3 . The first column shows the effect sizes of non-equivalence for each of the items (dMACS), and the last four columns show the factor loadings and the intercepts for the OSA and non-OSA samples.
A range of non-equivalence was found in the subscales. The broadest range of effect sizes was observed for the Anxiety subscale, in which effects ranged from very small (e.g., 0.12 for the item Scared without reason) to medium (e.g., 0.57 for the item Action of my heart in the absence of physical exertion). Inspection of the loadings and intercepts indicated that the items Dryness in mouth and Action of my heart in the absence of physical exertion produced the largest differences between the two samples, particularly at the upper end of the latent trait continuum (see Nye & Drasgow, 2011) . Figure 1 illustrates that the impact of DIF on the scores for these two items (1a. Dryness of mouth; 1b. Action of my heart) contrasted with a third item (1c. Worry about panic and making a fool of self), which had an effect size of 0.31. For the first two items, at higher levels of anxiety (the latent trait), individuals with OSA endorsed a lower severity score than those without OSA. That is, DIF produced lower responses on the subscale item for similar levels of the latent trait of anxiety for the OSA sample than the non-OSA sample. For the third item illustrated, the effect was the opposite: OSA individuals with higher levels of anxiety scored higher on that item than those without OSA. Inspection of the pattern of loadings across the anxiety items revealed that four had higher loadings for the non-OSA sample and two for the OSA sample. A small range of non-equivalence was identified in the This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Depression and Stress subscales, but there were no meaningful differences in the way DIF affected the way these items were being responded to between the samples. Collapsing across all of the items within each subscale revealed only small effects of DIF on the scales' properties (see Table 4 ). The largest difference in mean was Ϫ0.49 points for the Stress subscale and the smallest, despite the effects previously described, was Ϫ0.29 points for the Anxiety subscale. The negative values in this column suggest that DIF results in higher means for the OSA sample. However, these differences were in raw score points; therefore, compared with the non-OSA sample, the OSA sample had means that were 0.39 points higher for the Depression subscale, 0.29 points higher for the Anxiety subscale, and 0.49 points higher for the Stress subscale because of DIF. Because these differences were at the scale level, they must be interpreted relative to a 42-point maximum score (i.e., seven items with four response options coded 0 to 3, doubled to 42), which indicates that they are small. DIF accounted for 97.5%, 100%, and 98% of the observed Note. OSA ϭ Obstructive Sleep Apnea; MACS ϭ mean and covariance structure. dMACS values are effect sizes: 0.20 ϭ small, 0.50 ϭ medium, 0.80 ϭ large. a Indicates referent item. ‫ء‬ Latent means were set to 0 on dMACS (see Nye & Drasgow, 2011) . Factor loadings are unstandardized. Subscript numbers that are the same within each subscale indicate that the error terms for these item pairs were permitted to correlate. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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differences in means between the samples on the Depression, Anxiety, and Stress subscales, respectively. Therefore, the majority of the observed differences between the means of the two samples were due to DIF, rather than true mean differences, but the overall effect on scale mean scores was negligible. In regards to the variance of the subscales, in the most extreme case, nonequivalence accounted for variance 1.67 points higher on the Anxiety subscale in the OSA sample than the non-OSA sample. In addition, DIF accounted for 0%, 135.77%, and 9.34% of the observed differences in variance among the samples on the Depression, Anxiety, and Stress subscales, respectively. Therefore, the observed differences between the variances of the two samples on the Anxiety subscale were likely due to DIF, albeit the variances were not large to begin with.
Discussion
The present study explored Lovibond and Lovibond's (1995) correlated three-factor structure of the DASS-21 in OSA and non-OSA samples by means of CFA and examined measurement invariance. The results showed that Lovibond and Lovibond's (1995) correlated three-factor structure did not fit the OSA sample as well as the non-OSA sample. In addition, configural invariance was not found, suggesting that both samples may be differently interpreting the constructs of the DASS-21 (Cheung & Rensvold, 2002; Milfont & Fischer, 2010) . Inspection of the individual items within the subscales to determine the source of this difference indicated that overall, DIF led to slightly higher factor means and variances for each of the subscales in the OSA sample compared with the non-OSA sample. However, the actual difference that this Note. OSA ϭ Obstructive Sleep Apnea; DIF ϭ differential item functioning; ⌬M ϭ amount of observed mean differences that can be attributed to DIF (referent group -focal group). Observed mean difference ϭ DIF ϩ true mean differences. ⌬Var ϭ difference in the variances of the subscale due to DIF. Differences in observed variance ϭ DIF ϩ true variances. For all difference metrics, negative values indicate larger values in the OSA sample than in the non-OSA sample. This document is copyrighted by the American Psychological Association or one of its allied publishers.
produced in mean subscale scores was small (between just 0.29 and 0.49 of a point; i.e., less than half of a point across any subscale overall). Therefore, on balance, we take the view that the degree of DIF for each of the Depression, Anxiety, and Stress subscales of the DASS-21 is not sufficient to cause concern when using the full-scale DASS-21 to assess negative affect in an OSA sample.
It is interesting to note that there was no impact of the symptom overlap within the Stress subscale. However, inspection of the problematic items within the Anxiety subscale does challenge our understanding of the impact of symptom overlap on the measurement of negative affect in clinical disorders or chronic illness. Although the mean of the Anxiety subscale differed only by 0.29 of a point, there were modest problems with two symptoms within this subscale. For two physiological symptoms of anxiety (items: Dryness in mouth, and Action of my heart in the absence of physical exertion), small to medium-sized differences in the way these items were endorsed were evident, particularly at the upper end of the latent trait continuum. That is, highly anxious respondents in the OSA and non-OSA samples responded differently to these items. Although dryness of the mouth was identified as an overlapping symptom with OSA, heart action was not categorized as an overlapping symptom in Nanthakumar et al. (2016) . However, on reflection, OSA is associated with increased risk of atrial fibrillation (see Gami et al., 2007) , which may be experienced as heartbeat changes in the absence of exertion. Strikingly, the effect of symptom overlap for these items produced lower severity scores in the OSA sample, despite higher mean subscale scores. This contrasts markedly with the evidence that overlapping symptoms of depression and OSA lead to inflation of depression scores, thus producing higher prevalence estimates of depression in OSA (Nanthakumar et al., 2016) . Therefore, the impact of symptom overlap on depressive symptomology may have separate, and opposing effects, depending on the nature of the symptom and the clinical disorder or chronic illness. Critically, however, from the point of view of each DASS-21 subscale, these opposing effects appear to cancel each other out, making the DASS-21 suitable for use in OSA in its entirety.
The present study is the first to examine whether the fullscale of the DASS-21 is suitable for use in OSA and examine the impact of symptom overlap. Although individuals were recruited from an epidemiological sample, there was a limited age range because the sample consisted of baby boomers who were on the electoral roll. It is possible that there may be differential effects in measurement invariance in younger or older age groups (Gabbay & Lavie, 2012) . Furthermore, although an ApneaLink has been found to have adequate sensitivity and specificity as a screening tool for diagnosing OSA, overnight PSG, which is the gold standard for diagnosing OSA, was not available (Mansfield, Antic, & McEvoy, 2013; Ragette et al., 2010) . In addition, because individuals in the non-OSA sample were matched to the OSA sample on age, gender, and as close as possible to BMI, we had insufficient participants to select non-OSA controls with an AHI of Յ10 or even Յ5. That said, 88% of the non-OSA sample had an AHI of Յ10 and 59% had an AHI of Յ5. Future studies may wish to recruit a wide age range, diagnose OSA with PSG, and use a lower AHI cutoff (e.g., AHI Յ5) to select individuals in the non-OSA sample to further examine any difference between OSA and non-OSA samples and to examine measurement invariance.
Although this study suggests that the full-scale DASS-21 is suitable for use in OSA, this is clearly an area that warrants greater consideration in relation to OSA; with respect to other negative affect measures that may suffer greater DIF; and in other clinical disorders or chronic illness conditions such as insomnia (Carney, Ulmer, Edinger, Krystal, & Knauss, 2009 ), Parkinson's disease (Schrag et al., 2007) , and diabetes (Anderson, Freedland, Clouse, & Lustman, 2001 ) because DIF may impact the suitability of other questionnaires used to assess negative affect in these conditions by inflating or reducing the degree to which symptoms are endorsed in unexpected or confounding ways.
